Imaging and therapy in prostate cancer using PSMA radioligands

Mitesh Naik; Sairah R Khan; Valerie Lewington; Amar Challapalli; Amy Eccles; Tara D Barwick

doi:10.1093/bjr/tqae092

Imaging and therapy in prostate cancer using PSMA radioligands

Br J Radiol. 2024 May 11:tqae092. doi: 10.1093/bjr/tqae092. Online ahead of print.

Authors

Mitesh Naik¹, Sairah R Khan¹, Valerie Lewington², Amar Challapalli³, Amy Eccles¹, Tara D Barwick¹

Affiliations

¹ Imaging Department, Imperial College Healthcare NHS Trust, London.
² Division of Imaging Sciences and Biomedical Engineering, Kings College London, London, WC2R 2LS.
³ Department of Clinical Oncology, Bristol Cancer Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, BS2 8ED.

PMID: 38733571
DOI: 10.1093/bjr/tqae092

Abstract

Prostate specific membrane antigen (PSMA)-directed PET imaging has rapidly transformed prostate cancer workup over the past decade and paved the way for a theranostic approach using 177Lu-labelled PSMA radioligand therapy. This review gives an overview of the underlying principles behind PSMA as a target; the current use of PSMA PET in prostate cancer imaging and benefits compared to conventional imaging; and therapeutic applications including optimisation of patient selection. It also explores the evidence base of PSMA PET for other indications not in routine clinical use and the future of PSMA-directed radioligand therapy.

Keywords: Prostate cancer; lutetium; prostate specific membrane antigen (PSMA); theranostics.